#2 Case study report: Neridronate Treatment for CRPS in right foot and knee for 7 months
General details | Patient’s info |
---|---|
Gender: | Female |
Age: | 61 at the time of treatment |
Home Country: | American |
Duration of illness: | 7 months prior to Neridronate Treatment |
Cause: | Total knee replacement |
Symptoms: | Burning, stinging pain and always a higher temperature in the affected limb (compared to other body parts), color changes in the knee, it often turns red. Painful even when slightly touched, sensitive to sheet and pants. Muscle tightness, spasm, cramping. The pain increases with activities, putting weight and at night. |
Clinical evaluation: | CRPS diagnosis. Allodynia in the right knee. Knee discoloration, sensitive to light touch, diminished sensation around the knee incisions site. Antalgic gait. |
Period of treatment in Italy: | March 2017 |
WHY THE PATIENT DECIDED TO UNDERGO THE NERIDRONATE TREATMENT IN ITALY
The patient tried different treatments before, which brought very light results. She took a lot of medications.
After finding out about the Neridronate treatment in Italy, she discussed the option with her pain management doctor and decided to undergo the treatment.
MEDICAL TREATMENT THE PATIENT UNDERWENT IN ITALY
Complex regional pain syndrome (CRPS) is a severely painful and disabling disease for which a multitude of therapeutic interventions have been proposed. In the past two decades, only Bisphosphonates gained credibility. In recent years, more convincing evidence has become available on the use of parenteral Neridronate. Since 2014, this drug is registered and marketed in Italy for the treatment of CRPS. To date, the only therapeutic schedule that is recognized to be able to confer benefit is the intravenous (IV) administration of 100 mg given 4 times.
4 neridronate infusions (100mg, I.v. in saline Solution 0,9% 250 ml)
See the Official Study on the Oxford Academics website: https://academic.oup.com/rheumatology/article/52/3/534/1777330
DAILY REPORT
DAY 1: arrival at the Milan airport Malpensa, meeting with the personal Health Planner and drive to the Vicenza hotel. Check in, briefing focused on next days, rest.
DAY 2: meeting with the Health Planner, short walk in Vicenza and rest.
DAY 3: meeting with the Health Planner, visit with the Rheumatologist Doctor, first Neridronate infusion.
DAY 4: meeting with the Health Planner, the patient feels quite well but tired.
DAY 5: meeting with the Health Planner, second Neridronate infusion. The patient reports some side effects, such as tiredness and bone ache.
DAY 6: meeting with the Health Planner and tourism in Verona. The patient still reports the previous side effects, but she is glad to walk a bit and tour Italy.
DAY 7: meeting with the Health Planner, third Neridronate infusion. The patient is still experiencing light side effects, but she is in a positive mood.
DAY 8: meeting with the Health Planner and tourism in Bassano del Grappa and Marostica.
DAY 9: meeting with the Health Planner, fourth Neridronate infusion. The patient feels much better than the previous days and she does not report side effects anymore.
DAY 10: meeting with the Health Planner and tourism in Venice. The patient feels well and discovering the beauty of Venice makes her even happier since she has completed her treatment.
Day 11: meeting with the Health Planner, follow up visit with the Rheumatologist Doctor.
Day 12: meeting with the Health Planner and rest day.
Day 13: meeting with the Health Planner and drop-off at the Milan airport for the flight back home. The patient feels well, and she is not worried about the long travel that awaits her.
FOLLOW UP
APRIL 2017 (1 month after treatment): the patient feels better but has several cramps. The doctor who followed her in Italy prescribed some supplements that solved the issue.
JUNE 2017 (3 months after treatment): the patient is totally pain free and symptoms free.
AUGUST 2018 (15 months after treatment): the patient is well, she has no more pain, does not take any of her pain medications anymore and is back to all her activities. She reports light pain when she walks or works longer, but it goes away with just some rest.
AUGUST 2021 (4 and a half years after treatment): the patient tried to get off all medications but went back to only 1 pill at night. She could perform many more activities.
APRIL 2023 (6 years after treatment): the patient celebrates her full, lasting remission, totally pain and symptoms free.
CONCLUSION
This case proves that the best and most consistent results can be expected when CRPS is treated with Neridronate in the early stages, even better if it is within 6 months from the onset of the illness.
The patient underwent the treatment 7 months after the onset of her symptoms and the beginning of her CRPS. Just 3 months after the treatment, she was in full remission, and she still is after 6 years. The outcomes from the Neridronate treatment are generally long lasting so that the patient can go back to their lives and activities as they used to.
Reviews
There are no reviews yet.